4.5 Article

Successful development and clinical translation of a novel anterior lamellar artificial cornea

Journal

Publisher

WILEY
DOI: 10.1002/term.2951

Keywords

advanced therapy medicinal products (ATMPs); clinical translation; cornea; preclinical research; regulatory issues; tissue-engineered anterior human cornea (TEAHC); tissue engineering

Funding

  1. Regional Ministry of Health
  2. Spanish Ministry of Economy and Competitiveness (Carlos III Institute of Health) [FIS PI14/0955 FIS PI17/0391]
  3. Spanish Ministry of Health, Social Policy and Equity (Carlos III Institute of Health) [EC10-285]

Ask authors/readers for more resources

Blindness due to corneal diseases is a common pathology affecting up to 23 million individuals worldwide. The tissue-engineered anterior human cornea, which is currently being tested in a Phase I/II clinical trial to treat severe corneal trophic ulcers with preliminary good feasibility and safety results. This bioartificial cornea is based on a nanostructured fibrin-agarose biomaterial containing human allogeneic stromal keratocytes and cornea epithelial cells, mimicking the human native anterior cornea in terms of optical, mechanical, and biological behavior. This product is manufactured as a clinical-grade tissue engineering product, fulfilling European requirements and regulations. The clinical translation process included several phases: an initial in vitro and in vivo preclinical research plan, including preclinical advice from the Spanish Medicines Agency followed by additional preclinical development, the adaptation of the biofabrication protocols to a good manufacturing practice manufacturing process, including all quality controls required, and the design of an advanced therapy clinical trial. The experimental development and successful translation of advanced therapy medicinal products for clinical application has to overcome many obstacles, especially when undertaken by academia or SMEs. We expect that our experience and research strategy may help future researchers to efficiently transfer their preclinical results into the clinical settings.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available